Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study. (Q43418166)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Branka Polic

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Luka Stricevic

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Vitomir Metlicic

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Radenka Kuzmanic-Samija

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Tanja Kovacevic

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ivana Erceg Ivkosic

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Julije Mestrovic

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

14 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

published in

Vienna Clinical Weekly

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

126

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

3-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

133-137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24337590%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00508-013-0475-3

3 March 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

A randomized study of alglucosidase alfa in late-onset Pompe's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Immune Modulation Therapy in a CRIM-Positive and IgG Antibody-Positive Infant with Pompe Disease Treated with Alglucosidase Alfa: A Case Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Elimination of antibodies to recombinant enzyme in Pompe's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

The impact of antibodies in late-onset Pompe disease: a case series and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-013-0475-3

Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease

21 January 2018

1 reference

12 December 2020

High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa

1 reference

12 December 2020

Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease

1 reference

12 December 2020

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

1 reference

12 December 2020